Adverum Biotechnologies Initiated at Outperform by Oppenheimer
Adverum Biotechnologies Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $25
Oppenheimer analyst Francois Brisebois initiates coverage on $Adverum Biotechnologies(ADVM.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a succes
Express News | Adverum Biotechnologies Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $25
Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit
REDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly
Express News | Adverum Biotechnologies Announces Appointments of DR. Rabia Gurses Ozden as Chief Medical Officer and DR. Szilárd Kiss as a Member of the Board of Directors
Strong Buy Rating for Adverum Biotechnologies Amid Anticipated Positive Phase 2 Results and Market Undervaluation
Adverum Biotechnologies Is Maintained at Buy by Truist Securities
Adverum Biotechnologies Is Maintained at Buy by Truist Securities
Express News | Truist Securities Maintains Buy on Adverum Biotechnologies, Maintains $60 Price Target
Adverum Biotechnologies (ADVM) Receives a Buy From Truist Financial
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
Express News | HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target
Express News | Adverum Biotechnologies Q1 2024 Adj EPS $(1.50) Misses $(1.40) Estimate
Express News | Adverum Biotechnologies Inc: $193.3 Mln in Cash, Cash Equivalents and Short-Term Investments Expected to Fund Operations Into Late 2025
Adverum Biotechnologies | 10-Q: Quarterly report
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations
Adverum Biotechnologies 1Q Loss/Shr $1.50 >ADVM
Adverum Biotechnologies 1Q Loss/Shr $1.50 >ADVM
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
Adverum Biotechnologies a New Buy at H.C. Wainwright on Wet AMD Gene Therapy
Adverum Biotechnologies Price Target Announced at $30.00/Share by HC Wainwright & Co.
Adverum Biotechnologies Price Target Announced at $30.00/Share by HC Wainwright & Co.
Express News | Adverum Biotechnologies, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating